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Summary In a previous study (Burkitt lymphoma study I, BL I) between 1982 and 1984, we
used a multidrug rotating chemotherapy schedule, now known as 'GRAB', to treat 24 Iraqi
children with non-localised BL (Murphy stages II, III and IV). At the time of reporting, actuarial
survival was 50% (current actual survival 42%) and the major morbidity and mortality was not
from resistant or relapsed lymphoma, but from complications of the tumour lysis syndrome,
sepsis and early abdominal surgery. The study (BL II) reported here was carried out between
1984 and 1986; we used GRAB to treat 24 newly and consecutively diagnosed children with
advanced Burkitt lymphoma but discouraged early 'debulking' surgery and paid special attention
to supportive care during the first two weeks of treatment. As in BL I, no radiotherapy was used.
Twenty patients (83.8%) attained complete remission: 17 (71%), including three of the seven
stage IV patients, survive continuously disease-free at a median of 26 months (range 18-36
months) from diagnosis. We have previously pointed out that GRAB, without radiotherapy, may
be especially suited for use in some developing countries. From this study we conclude that, with
appropnate supportive care and minimal surgery, survival rates over 50% may be achieved. Our
next studies are aimed at defining a 'good risk' group of patients, who may be curable without
alkylating agents and a 'poor risk' group, who need more intensive therapy.
Burkitt lymphomas comprise about one-half of all childhood
non-Hodgkin's lymphomas presenting to our centre. These
rapidly growing tumours are very chemosensitive and rapid
progress in treatment has been made during the past decade.
Before 1982, treatment in Iraq was with surgery, non-
intensive chemotherapy and, sometimes, radiotherapy but
survival was less than 10% (Al-Attar et al., 1979). Between
1982 and 1984 we used the 'GRAB' (good risk (NHL) and
Burkitt) chemotherapy regimen with much improved results
(Al-Attar et al., 1986). At the time of reporting (August
1986) 50% of patients were surviving free of disease; cur-
rently (May 1988) there are 10 long-term survivors, all more
than 46 months after cessation of therapy (range 46-72
months, median 63 months) and probably cured. In BL I, a
number of deaths were caused by: (a) complications of the
tumour lysis syndrome (Lynch et al., 1977), especially hyper-
uricaemia and hyperkalaemia, and (b) septic complications
of 'debulking' surgery carried out before referral to our unit
(Al-Attar et al., 1986). In this study, BL II, we used the same
GRAB chemotherapy, but discouraged debulking abdominal
surgery and paid close attention to metabolic complications
during the first two weeks of treatment. The objective was to
determine whether, with this approach, we could further
improve survival.
Patients and methods
Between May 1985 and November 1986, 24 consecutively
diagnosed and previously untreated children with stages II,
III and IV Burkitt lymphoma admitted to the paediatric
oncology unit of Medical City Hospital were entered on the
BL II study. Clinical details are given in Table I. There were'
19 boys and five girls (M:F 3.8:1), aged from 2 to 13 years,
(median 5.4 years). The nutritional status of several children,
as in BLI, was poor. The diagnosis was made by histo-
pathological criteria in 22 cases (six biopsies ofjaw tumours
and 16 open biopsies of abdominal tumours) and in the
remaining two by recognition of characteristic L-3 blasts
(Bennett et al., 1976) in bone marrow or pleural fluid.
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Because of lack of suitable testing facilities, neither immuno-
phenotyping or karyotyping of blasts nor EB virus serdlogy
were carried out.
The following staging investigations were performed: full
blood count, unilateral bone marrow and trephine biopsy,
cerebrospinal fluid (CSF) cell count and cytospin, and chest
X-ray. Eight patients had abdominal ultrasonography.
Staging was by the Murphy (1978) system.
Supportive care included allopurinol, intravenous fluids,
careful alkalinisation of urine during remission induction,
antibiotics and blood/platelet transfusions as necessary.
Before each treatment course, as in BL I, the children were
examined clinically to assess tumour response and blood
count and renal/liver function tests were performed. Single
site bone marrow aspirate was carried out every 8 weeks and
CSF cell count and cytology after each of six serial lumbar
punctures. Every 2 months after completion of chemo-
therapy, patients were examined clinically and underwent
single site marrow aspiration plus trephine biopsy and CSF
examination. Chest X-rays and intravenous urograms were
repeated at 6 months off treatment. Thereafter patients were
monitored regularly but only with clinical examination.
Three children had stage II tumours and 14 stage III
(Table I). Each of the seven stage IV patients had bone
marrow involvement; one of them (case 5) also presented
with acute bilateral visual loss, attributed to optic nerve
infiltration by lymphoma, but this child and the six others
had normal CSF at the time of diagnosis. Five children,
including one with stage IV disease, had liver involvement
and in three there were ovarian masses. Other sites of disease
are noted in Table I.
Treatment, toxicity and survival
Two children (cases 1 and 9) had 'debulking' surgery before
referral to our unit. All children received the GRAB regime,
exactly as described in Al-Attar et al. (1986). There was no
radiotherapy. Two patients (cases 13 and 17) died from
complications of the tumour lysis syndrome (Lynch et al.,
1977), within one week of receiving the first course ('CHOP')
in the GRAB regime. Thereafter, treatment was well toler-
ated and usually administered as an outpatient. Two children
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Table I Staging and sites of disease in 24 patients with Burkitt's lymphoma
Case
no. Stage Abdomen Head and neck Bone marrow Other sites
1 II S&N
2 III M - Liver
3 IV M - +
4 III M
5 IV M Jaw + Optic nerves
6 III M
7 II - Bilateral jaw
8 III M -
9 II S&N -
10 III M Orbit
11 III M Jaw
12 IV M Orbit + Liver
13 IV M - +
14 III M - Liver, ovaries
15 IV M - +
16 III M - - Liver, ovaries
17 III M - Pleural effusion
18 III M -
19 IV - Jaw + Pleural effusion
20 III M - Kidneys, ovaries
21 III M Jaw
22 III M - Pleural effusion
23 IV M Jaw +
24 III M - Liver, spleen
S, single tumour; M, multiple tumours; N, regional node involvement.
Table II Deaths in BL I compared with BL II
BLI BLH
No. in study 24 24
Early deaths 8 2
PR or progression 1 2
Relapses 2 3
PR, partial response (see text).
(cases 19 and 20) showed only partial response to treatment
and died at 2 months and 10 months, respectively, from
progressive disease. Lymphoma recurred in only three of the
20 patients who achieved complete clinical remission. One
child with stage III disease (case 10) had a central nervous
system (CNS) relapse and died 10 months from diagnosis; a
second patient (case 23) with stage IV disease relapsed in the
CNS at 8 months after diagnosis and, after a temporary
remission with combined intrathecal methotrexate and cyto-
sine arabinoside, died at 15 months from diagnosis; a third
stage IV child (case 3) developed L3 blasts in peripheral
blood and died 15 months from diagnosis. See Table II for
comparison with BL I. Figure 1 indicates that the remaining
17 children (70.8%), including three stage IV patients, are in
continuous complete remission 13-36 months (median 28
months) after diagnosis and have been off treatment for 7-










In comparison with our prior experience, we were moder-
ately satisfied with the results of BLI, especially since
patients with overt stage IV disease were included. However,
we felt that the early mortality could be reduced by more
careful attention to supportive care during the first two
weeks of therapy, when our patients' poor nutritional status
(Al-Attar et al., 1986) was compounded by urate nephro-
pathy and other biochemical effects of the 'tumour lysis
syndrome'. In addition, a number of children had had early,
and possibly unnecessary, 'debulking' surgery before
transfer to our unit: before BL study II we encouraged our
surgical colleagues to refer patients to us before laparotomy
- a policy adhered to in 22/24 cases. The benefits of this
policy are shown in Table II. In BL II, there were only two
(8%) 'early' (and possibly avoidable) deaths compared with
eight (33%) in BL I. The majority of relapses after therapy
for advanced Burkitt lymphoma occur within 12 months
from diagnosis, so we hope the majority of survivors in
BL II have been cured.
At least one previous study (Ziegler, 1977) has suggested a
survival advantage for patients with BL undergoing initial
debulking surgery. However, the chemotherapy used in that
study was less intensive than ours. In our experience initial
adjuvant surgery, especially in patients in poor general
condition, may actually be a disadvantage because (a) it
increases the risk of complications, especially sepsis, (b) it
invariably delays the start of chemotherapy and (c) surgeons
are tempted to remove organs, such as the uterus and
ovaries, that are involved by tumour. In fact, two girl
survivors of BL I underwent bilateral salpingo-oophorectomy
and a boy developed a faecal fistula before referral to us:
castration of the girls would almost certainly have been
avoided if chemotherapy had been used first. Although a
randomised study, with 'quality of survival' as well as
'survival' as end-points, would be needed to prove the point
beyond doubt, we now discourage debulking surgery in our
unit.
In 'developed' countries, the prognosis for stage IV Bur-
I I | | | | kitt lymphoma patients is poor when conventional-dose
6 12 18 24 30 36 chemotherapy is given (Anderson et al., 1983; Magrath et
Months from diagnosis al., 1984). Even with more toxic, prolonged, labour-intensive
and expensive regimes (Murphy et al., 1986; Philip et al.,
Figure 1 Actuarial event-free survival in study BL II (n=24). 1984; Patte et al., 1986) the improvement in prognosis has
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been, at best, moderate. Disease-free survival, to date, of a
total of 5/14 (36%) stage IV patients in BL studies I and II
using therapy which, after remission, can be delivered in an
outpatient setting, is of particular interest. Unless the
'natural history' of Burkitt lymphoma is different in Iraq,
GRAB therapy seems worthy of study in Europe and North
America.
Children who have received alkylating agents are at
increased risk of both1 leukaemia (Anonymous, 1977) and
solid tumours (Tucker et al., 1987). In fact, one child in
study BL I developed a tibial Ewing's sarcoma 4.5 years
after completion of GRAB. Its oncogenicity, as well as its
sterilising potential - particularly in boys, who outnumber
girls 3:1 in most Burkitt series - are potent reasons for
trying to eliminate cyclophosphamide from treatment sche-
dules, particularly those for 'good risk' patients.
We have confirmed that a majority of Iraqi patients with
advanced Burkitt lymphoma achieve complete remission with
the GRAB regimen, without radiotherapy. It is likely that
most patients attaining complete remission will be long-term
survivors. The omission of debulking abdominal surgery has
not apparently prejudiced disease-free survival and has pro-
bably contributed to the improved results seen in this study,
compared with BL I. We are now directing our attention
towards identification of a 'low risk' group of children in
whom treatment can be refined and a 'high risk' group in
whom treatment should be intensified. Initially we plan to
investigate, for high risk patients, the so-called 'MACHO'
schedule (I.M. Hann et al., unpublished observations) which
incorporates high dose systemic cytosine arabinoside and
methotrexate as well as triple intrathecal chemotherapy. For
low risk patients, the elimination of cyclophosphamide from
the GRAB schedule seems a worthwhile goal. We have
already commenced pilot studies of 'HOP-GRAB' (GRAB)
minus cyclophosphamide) in London.
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